Nuclear Medicine and Biology
Volume 36, Issue 4 , Pages 371-378 , May 2009

Characterization, biodistribution and small-animal SPECT of I-125-labeled c-Met binding peptide in mice bearing c-Met receptor tyrosine kinase-positive tumor xenografts

  • Eun-Mi Kim

      Affiliations

    • Department of Nuclear Medicine, Chonbuk National University Medical School and Hospital, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • Research Institute of Clinical Medicine, Chonbuk National University Hospital, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • Cyclotron Research Center, Chonbuk National University Hospital, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • ,
  • Eun-Hye Park

      Affiliations

    • Department of Nuclear Medicine, Chonbuk National University Medical School and Hospital, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • Research Institute of Clinical Medicine, Chonbuk National University Hospital, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • Cyclotron Research Center, Chonbuk National University Hospital, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • ,
  • Su-Jin Cheong

      Affiliations

    • Department of Nuclear Medicine, Chonbuk National University Medical School and Hospital, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • Research Institute of Clinical Medicine, Chonbuk National University Hospital, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • Cyclotron Research Center, Chonbuk National University Hospital, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • ,
  • Chang-Moon Lee

      Affiliations

    • Department of Nuclear Medicine, Chonbuk National University Medical School and Hospital, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • Research Institute of Clinical Medicine, Chonbuk National University Hospital, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • Cyclotron Research Center, Chonbuk National University Hospital, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • ,
  • Dong Wook Kim

      Affiliations

    • Department of Nuclear Medicine, Chonbuk National University Medical School and Hospital, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • Research Institute of Clinical Medicine, Chonbuk National University Hospital, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • Cyclotron Research Center, Chonbuk National University Hospital, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • ,
  • Hwan-Jeong Jeong

      Affiliations

    • Department of Nuclear Medicine, Chonbuk National University Medical School and Hospital, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • Research Institute of Clinical Medicine, Chonbuk National University Hospital, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • Cyclotron Research Center, Chonbuk National University Hospital, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • Corresponding Author InformationCorresponding author. Department of Nuclear Medicine, Chonbuk National University Medical School, Jeonju-si, Jeonbuk 561-712, Republic of Korea. Tel.: +82 63 250 1674; fax: +82 63 250 1676.
    • ,
  • Seok Tae Lim

      Affiliations

    • Department of Nuclear Medicine, Chonbuk National University Medical School and Hospital, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • Research Institute of Clinical Medicine, Chonbuk National University Hospital, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • Cyclotron Research Center, Chonbuk National University Hospital, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • ,
  • Myung-Hee Sohn

      Affiliations

    • Department of Nuclear Medicine, Chonbuk National University Medical School and Hospital, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • Research Institute of Clinical Medicine, Chonbuk National University Hospital, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • Cyclotron Research Center, Chonbuk National University Hospital, Jeonju-si, Jeonbuk 561-712, Republic of Korea
    • ,
  • Kisu Kim

      Affiliations

    • Cancer Research Institute, Seoul National University College of Medicine, Seoul 110-799, Republic of Korea
    • ,
  • Junho Chung

      Affiliations

    • Cancer Research Institute, Seoul National University College of Medicine, Seoul 110-799, Republic of Korea

Received 19 September 2008 ,Revised 9 January 2009 ,Accepted 13 January 2009.

References 

  1. Wu Y, Zhang X, Xiong Z, Cheng Z, Fisher DR, Liu S, et al. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide. J Nucl Med. 2005;46:1707–1718
  2. Puri N, Ahmed S, Janamanchi V, Tretiakova M, Zumba O, Krausz T, et al. c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res. 2007;13:2246–2253
  3. Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 2005;225:1–26[Review]
  4. Lamszus K, Laterra J, Westphal M, Rosen EM. Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas. Int J Dev Neurosci. 1999;17:517–530
  5. Abounader R, Laterra J. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro-oncol. 2005;7:436–451
  6. Eckerich C, Zapf S, Fillbrandt R, Loges S, Westphal M, Lamszus K. Hypoxia can induce c-Met expression in glioma cells and enhance SF/HGF-induced cell migration. Int J Cancer. 2007;121:276–283
  7. Kim K, Hur Y, Ryu EK, Rhim JH, Choi CY, Baek CM, et al. A neutralizable epitope is induced on HGF upon its interaction with its receptor cMet. Biochem Biophys Res Commun. 2007;354:115–121
  8. Parry JJ, Kelly TS, Andrews R, Rogers BE. In vitro and in vivo evaluation of 64Cu-labeled DOTA-linker-bombesin(7–14) analogues containing different amino acid linker moieties. Bioconjug Chem. 2007;18:1110–1117
  9. Parry JJ, Andrews R, Rogers BE. MicroPET imaging of breast cancer using radiolabeled bombesin analogs targeting the gastrin-releasing peptide receptor. Breast Cancer Res Treat. 2007;101:175–183
  10. Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev. 2002;13:41–59
  11. Tseng JR, Kang KW, Dandekar M, Yaghoubi S, Lee JH, Christensen JG, et al. Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET. J Nucl Med. 2008;49:129–134
  12. Guerin C, Luddy C, Abounader R, Lal B, Laterra J. Glioma inhibition by HGF/NK2, an antagonist of scatter factor/hepatocyte growth factor. Biochem Biophys Res Commun. 2000;273:287–293
  13. Jiang WG, Martin TA, Parr C, Davies G, Matsumoto K, Nakamura T. Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit Rev Oncol Hematol. 2005;53(1):35–69
  14. Puri N, Khramtsov A, Ahmed S, Nallasura V, Hetzel JT, Jagadeeswaran R, et al. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res. 2007;67(8):3529–3534
  15. Chu SH, Zhang H, Ma YB, Feng DF, Zhu ZA, Yuan XH, et al. c-Met antisense oligodeoxynucleotides as a novel therapeutic agent for glioma: in vitro and in vivo studies of uptake, effects, and toxicity. J Surg Res. 2007;141(2):284–288
  16. Martens T, Schmidt NO, Eckerich C, Fillbrandt R, Merchant M, Schwall R, et al. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res. 2006;12(20):6144–6152
  17. Czernin J, Weber WA, Herschman HR. Molecular imaging in the development of cancer therapeutics. Annu Rev Med. 2006;57:99–118
  18. De Nardo SJ. Combined molecular targeting for cancer therapy: a new paradigm in need of molecular imaging. J Nucl Med. 2006;47:4–5
  19. Rudin M, Weissleder R. Molecular imaging in drug discovery and development. Nat Rev Drug Discov. 2003;2:123–131
  20. Inoue T, Tomiyoshi K, Higuichi T, et al. Biodistribution studies on L-3-[fluorine-18]fluoro-α-methyl tyrosine: a potential tumor-detecting agent. J Nucl Med. 1998;39:663–667
  21. Shikano N, Kawai K, Flores LG, Nishii R, Kubota N, Ishikawa N, et al. An artificial amino acid, 4-iodo-l-meta-tyrosine: biodistribution and excretion via kidney. J Nucl Med. 2003;44:625–631

☆ This work was supported by the Nuclear R&D program through the Korea Science and Engineering Foundation funded by the Ministry of Science and Technology (M20702000003-08N0200-00310).

PII: S0969-8051(09)00004-3

doi: 10.1016/j.nucmedbio.2009.01.005

Nuclear Medicine and Biology
Volume 36, Issue 4 , Pages 371-378 , May 2009

Article Tools

* Image Usage & Resolution